Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease - Clinical practice recommendations

Parkinsonism and Related Disorders

Volumn 21, Issue 9, 2015, Pages 1023-1030

  Trenkwalder, Claudia ^a,i   Chaudhuri, K Ray ^b   García Ruiz, Pedro J ^c   LeWitt, Peter ^d   Katzenschlager, Regina ^e   Sixel Döring, Friederike ^a,j   Henriksen, Tove ^f   Sesar, Ángel ^g   Poewe, Werner ^h   Baker, Mary ^k   Ceballos Baumann, Andres ^l   Deuschl Gunther ^m   Drapier, Sophie ⁿ   Ebersbach, Georg ^o   Evans, Andrew ^p   Fernandez, Hubert ^q   Isaacson, Stuart ^r   van Laar, Teus ^s   Lees, Andrew ^t   Lewis, Simon ^u   Castrillo , Juan Carlos Martínez ^v   Martinez Martin, Pablo ^w   Odin, Per ^x   O'Sullivan, John ^y   Tagaris, Georgios ^z   Wenzel, Karoline ^aa   more..

^a Paracelsus Elena Hospital   (Germany)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DANUBE HOSPITAL   (Austria)

^f BISPEBJERG HOSPITAL   (Denmark)

^g Instituto de Salud Carlos III   (Spain)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^j PHILIPPS UNIVERSITY MARBURG   (Germany)

^k European Brain Council   (Belgium)

^l NEUROLOGISCHES KRANKENHAUS MÜNCHEN   (Germany)

^m UNIVERSITY OF KIEL   (Germany)

ⁿ RENNES UNIVERSITY HOSPITAL   (France)

^o Movement Disorder Clinic   (Germany)

^p ROYAL MELBOURNE HOSPITAL   (Australia)

^q LERNER RESEARCH INSTITUTE   (United States)

^r FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^s UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^t UNIVERSITY COLLEGE LONDON   (United Kingdom)

^u UNIVERSITY OF SYDNEY   (Australia)

^v HOSPITAL RAMÓN Y CAJAL   (Spain)

^w INSTITUTO DE SALUD CARLOS III   (Spain)

^x LUND UNIVERSITY HOSPITAL   (Sweden)

^y UNIVERSITY OF QUEENSLAND   (Australia)

^z KAT HOSPITAL   (Greece)

^aa MEDICAL UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

Apomorphine injection; Apomorphine pump; Clinical practice; Parkinson's disease; Treatment

Indexed keywords

APOMORPHINE; ANTIPARKINSON AGENT;

CLINICAL PRACTICE; CONSENSUS; CONSENSUS DEVELOPMENT; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EXPERT SYSTEM; HEALTH CARE PERSONNEL; HUMAN; INFUSION PUMP; MEDICAL PRACTICE; NONHUMAN; ORAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; TRANSDERMAL DRUG ADMINISTRATION; TREATMENT RESPONSE; STANDARDS;

ANTIPARKINSON AGENTS; APOMORPHINE; CONSENSUS; HUMANS; PARKINSON DISEASE; PRACTICE PATTERNS, PHYSICIANS';

EID: 84940615116     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.06.012     Document Type: Review

References (39)

1. Schwab R.S., Amador L.V., Lettvin J.Y. Apomorphine in Parkinson's disease. Trans. Am. Neurol. Assoc. 1951, 56:251-253.
2. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., Kanovsky P., et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European federation of neurological societies (EFNS) and the movement disorder society-European section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur. J. Neurol. 2006, 13:1186-1202.
3. Antonini A., Tolosa E., Mizuno Y., Yamamoto M., Poewe W.H. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol. 2009, 8:929-937.
4. Fox S.H., Katzenschlager R., Lim S.Y., Ravina B., Seppi K., Coelho M., et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 2011, 26(Suppl. 3):S2-S41.
5. Isaacson S.H., Hubble J., Gullo K. Apokyn for Morning Akinesia Trial (AM IMPAKT) 2013, World Congress of Neurology, Vienna, Austria.
6. Taylor H., Leitman R. The difficult lives of patients with Parkinson's disease. Health Care News 2003, 3.
7. Martinez-Martin P., Schapira A.H., Stocchi F., Sethi K., Odin P., MacPhee G., et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov. Disord. 2007, 22:1623-1629.
8. Schuepbach W.M., Rau J., Knudsen K., Volkmann J., Krack P., Timmermann L., et al. Neurostimulation for Parkinson's disease with early motor complications. N. Engl. J. Med. 2013, 368:610-622.
9. Fasano A., Daniele A., Albanese A. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol. 2012, 11:429-442.
10. Fasano A., Ricciardi L., Lena F., Bentivoglio A.R., Modugno N. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Eur. Rev. Med. Pharmacol. Sci. 2012, 16:79-89.
11. LeWitt P.A. Dopaminergic agonists in Parkinson's disease. Encyclopedia of Movement Disorders 2010, 332-336. Academic Press, Oxford. K. Kompoliti, L. Verhagen Metman (Eds.).
12. Deleu D., Hanssens Y., Northway M.G. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004, 21:687-709.
13. Gancher S.T., Bennett W., English J. Studies of renal function in animals chronically treated with apomorphine. Res. Commun. Chem. Pathol. Pharmacol. 1989, 66:163-166.
14. LeWitt P.A. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004, 62:S8-S11.
15. van Laar T., Jansen E.N., Essink A.W., Neef C., Oosterloo S., Roos R.A. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease. Clin. Neurol. Neurosurg. 1993, 95:231-235.
16. Ostergaard L., Werdelin L., Odin P., Lindvall O., Dupont E., Christensen P.B., et al. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry 1995, 58:681-687.
17. Dewey R.B., Hutton J.T., LeWitt P.A., Factor S.A. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch. Neurol. 2001, 58:1385-1392.
18. Pfeiffer R.F., Gutmann L., Hull K.L., Bottini P.B., Sherry J.H. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Park. Rel Disord. 2007, 13:93-100.
19. Pahwa R., Koller W.C., Trosch R.M., Sherry J.H. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J. Neurol. Sci. 2007, 258:137-143.
20. Wenzel K., Homann C.N., Fabbrini G., Colosimo C. The role of subcutaneous infusion of apomorphine in Parkinson's disease. Expert Rev. Neurother. 2014, 14:833-843.
21. Chaudhuri K.R., Critchley P., Abbott R.J., Pye I.F., Millac P.A. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet 1988, 2:1260.
22. Stocchi F., Vacca L., De Pandis M.F., Barbato L., Valente M., Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol. Sci. 2001, 22:93-94.
23. Katzenschlager R., Hughes A., Evans A., Manson A.J., Hoffman M., Swinn L., et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov. Disord. 2005, 20:151-157.
24. Garcia Ruiz P.J., Sesar Ignacio A., Ares Pensado B., Castro Garcia A., Alonso Frech F., Alvarez Lopez M., et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov. Disord. 2008, 23:1130-1136.
25. Stacy M., Bowron A., Guttman M., Hauser R., Hughes K., Larsen J.P., et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov. Disord. 2005, 20:726-733.
26. Todorova A., Ray Chaudhuri K. Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease. Park. Rel Disord. 2013, 19:1073-1078.
27. Ray-Chaudhuri K., Abbott R.J., Millac P.A. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment. J. Neurol. Neurosurg. Psychiatry 1991, 54:372-373.
28. Ellis C., Lemmens G., Parkes J.D., Abbott R.J., Pye I.F., Leigh P.N., et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Park. Rel Disord. 1997, 3:103-107.
29. Antonini A., Isaias I.U., Rodolfi G., Landi A., Natuzzi F., Siri C., et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J. Neurol. 2011, 258:579-585.
30. Alegret M., Valldeoriola F., Marti M., Pilleri M., Junque C., Rumia J., et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Mov. Disord. 2004, 19:1463-1469.
31. De Gaspari D., Siri C., Landi A., Cilia R., Bonetti A., Natuzzi F., et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry 2006, 77:450-453.
32. Daley D.J., Myint P.K., Gray R.J., Deane K.H. Systematic review on factors associated with medication non-adherence in Parkinson's disease. Park. Rel Disord. 2012, 18:1053-1061.
33. Bainbridge J.L., Ruscin J.M. Challenges of treatment adherence in older patients with Parkinson's disease. Drugs Aging 2009, 26:145-155.
34. Setter S.M. Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson's disease. Neurol. Clin. 2008, 26:S45-S63.
35. Gancher S.T., Nutt J.G., Woodward W.R. Time course of tolerance to apomorphine in parkinsonism. Clin. Pharmacol. Ther. 1992, 52:504-510.
36. Gancher S.T., Nutt J.G., Woodward W.R. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov. Disord. 1995, 10:37-43.
37. Gancher S., Nutt J. Tolerance to apomorphine develops and reverses rapidly. Mov. Disord. 2010, 25:803-804.
38. Poltawski L., Edwards H., Todd A., Watson T., Lees A., James C.A. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study. Mov. Disord. 2009, 24:115-118.
39. Hauser R.A., Isaacson S., Clinch T. Tigan/Apokyn Study I. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Park. Rel Disord. 2014, 20:1171-1176.